Summary of CeriBell (CBLL) FY Conference - June 03, 2025 Company Overview - CeriBell is focused on developing an AI-driven neural monitoring platform for seizure detection in acute care settings, specifically in ICUs and emergency departments [2][5] - The company has a total addressable market (TAM) of over $2 billion in the U.S. for seizure detection alone [5] Core Product and Technology - CeriBell's platform includes hardware and an AI-powered seizure detection algorithm, allowing for rapid EEG setup and monitoring [4][23] - The AI algorithm, named Clarity, continuously monitors EEG signals and alerts medical staff in real-time about seizure activity [23][24] - The system can set up EEG in minutes, contrasting with traditional methods that can take hours or days [23][25] Clinical Need and Impact - Seizures in ICU patients often go unnoticed due to the lack of symptoms, leading to high mortality rates if not detected early [7][11] - Early detection is critical; mortality rates increase significantly with delays in treatment [12][11] - CeriBell's technology addresses the bottlenecks of traditional EEG monitoring, which requires specialized technicians and can lead to delays in patient care [15][17] Commercial Performance - CeriBell reported $20.5 million in revenue last quarter, representing a 42% year-over-year growth [5] - The company is currently trending towards 600 hospitals, with a gross margin of 88% [5] - The revenue model consists of 25% from AI subscription fees and 75% from disposable headband sales [40][41] Market Expansion and Future Pipeline - CeriBell has expanded its TAM by qualifying for cloud-based operations in VA facilities and gaining FDA clearance for pediatric applications [49][50] - Future plans include submitting applications for neonate clarity and using EEG for other indications like delirium and stroke [58] Health Economics and Clinical Evidence - CeriBell's technology has shown to reduce unnecessary patient transfers by 94-100% and decrease length of stay in hospitals by an average of 4.1 days [36][37] - The company qualifies for existing EEG CPT codes, enhancing hospital reimbursement opportunities [38] - CeriBell has published over 35 peer-reviewed journals, demonstrating strong clinical evidence for its impact [39] Sales and Marketing Strategy - The sales force is divided into territory managers for account acquisition and clinical account managers for existing accounts [42] - The business model is characterized by high customer retention and consistent usage, making it difficult for competitors to lure away clients [44][46] Conclusion - CeriBell's innovative approach to seizure detection in acute care settings has the potential to significantly improve patient outcomes while also providing economic benefits to hospitals [60] - The company is well-positioned for future growth with a strong focus on expanding its technology and market reach [60]

Company Overview - Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA-cleared for detecting suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will present at the William Blair 45 Annual Growth Stock Conference [1] - The presentation is scheduled for Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time [2] - A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website [2]

CeriBell (CBLL) 2025 Conference May 14, 2025 01:55 PM ET Speaker0 From the Vice Analyst at Bank of America. I wanted to introduce our next speaker, Jane Chao, CEO of Cerebell, a newly public company. And so Jane, welcome, and you're going to go through a slide presentation. Speaker1 Thank you, Travis. I got this mic. Good. I don't need to if you can hear me well, I don't need to be in the mic. Right? Okay. Perfect. Well, good morning, everyone. Thank you for being here. I'm very excited to share our story. ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $20.5 million, reflecting a 42% increase from $14.4 million in Q1 2024 and an 11% increase from Q4 2024 [7][24] - Gross margin for Q1 2025 was 88%, compared to 86% in the prior year [25] - Net loss for Q1 2025 was $12.8 million, or a loss of $0.36 per share, compared to a loss of $8.5 million, or a loss of $1.56 per share in Q1 2024 [27] Business Line Data and Key Metrics Changes - Product revenue for Q1 2025 was $15.6 million, a 41% increase from $11 million in Q1 2024 [25] - Subscription revenue for Q1 2025 was $4.9 million, representing a 45% increase from $3.4 million in Q1 2024 [25] Market Data and Key Metrics Changes - As of March 31, 2025, the company had 558 active accounts, an increase of 29 during the first quarter [9] - The company estimates it currently serves about 3% of the U.S. population that could benefit from its technology [12] Company Strategy and Development Direction - The company aims to expand its account acquisition team to 55 territory managers by mid-2025 [13] - The focus remains on increasing awareness of the clinical and economic benefits of its products through direct engagement with clinicians and marketing initiatives [14] - The company plans to conduct a limited commercial release of its pediatric algorithm, with a full launch anticipated in subsequent years [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability using current cash on hand despite a dynamic trade environment [9] - The company expects full-year 2025 total revenue to range from $83 million to $87 million, up from prior guidance of $81 million to $85 million [28] - Management acknowledged potential impacts from increased tariffs but remains confident in maintaining gross margins in the mid-80% range [29][30] Other Important Information - The company received FDA clearance for its pediatric seizure detection algorithm, expanding its addressable patient population [15] - The company is one of only 51 companies to receive FedRAMP high authorization, validating its cybersecurity standards [10] Q&A Session Summary Question: What is driving the raise in guidance by more than the beat? - Management indicated that greater confidence in account acquisition and management strategies led to the guidance increase [35] Question: Can you elaborate on potential mitigation actions regarding tariffs? - Management mentioned strategies such as automation, cost negotiation with vendors, and potential reshoring plans to mitigate tariff impacts [41] Question: Will pediatric clarity contribute to the 2025 guidance? - Management confirmed that pediatric clarity will not impact the 2025 guidance but sees meaningful expansion potential in future years [48] Question: What is the opportunity for expansion within the customer base? - Management estimates a 70% opportunity for further penetration within existing accounts [66] Question: How is the competitive landscape? - Management stated that while there are emerging competitors, the company remains a clear category leader with unmatched technology and clinical evidence [70]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $20.5 million, reflecting a 42% increase from $14.4 million in Q1 2024 and an 11% increase from Q4 2024 [6][22] - Gross margin for Q1 2025 was 88%, compared to 86% in the prior year [23] - Net loss for Q1 2025 was $12.8 million, or a loss of $0.36 per share, compared to a loss of $8.5 million, or a loss of $1.56 per share in Q1 2024 [26] Business Line Data and Key Metrics Changes - Product revenue for Q1 2025 was $15.6 million, a 41% increase from $11 million in Q1 2024 [22] - Subscription revenue for Q1 2025 was $4.9 million, representing a 45% increase from $3.4 million in Q1 2024 [23] Market Data and Key Metrics Changes - As of March 31, 2025, the company had 558 active accounts, an increase of 29 during the first quarter [7] - The company estimates it currently serves about 3% of the U.S. population that could benefit from its technology [10] Company Strategy and Development Direction - The company aims to expand its account acquisition team to 55 territory managers by mid-2025 [11] - The focus remains on increasing awareness of the clinical and economic benefits of its technology through direct engagement with clinicians and marketing initiatives [12] - The company plans to conduct a limited commercial release of its pediatric algorithm, with a full launch anticipated in subsequent years [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability using current cash on hand despite a dynamic trade environment [7] - The company raised its full-year 2025 revenue guidance to a range of $83 million to $87 million, up from the previous guidance of $81 million to $85 million [27] - Management noted that they expect gross margins to remain in the mid-eighty percent range despite potential tariff impacts [28][29] Other Important Information - The company received FDA clearance for its pediatric seizure detection algorithm, expanding its addressable patient population [13] - The company is one of only 51 companies to receive FedRAMP high authorization, validating its cybersecurity standards [8] Q&A Session Summary Question: What is driving the raise in guidance by more than the beat? - Management indicated that greater confidence in account acquisition and management strategies led to the guidance increase [33] Question: Can you elaborate on potential mitigation actions regarding tariffs? - Management mentioned strategies such as automation, cost negotiation with vendors, and potential reshoring plans to mitigate tariff impacts [39] Question: How do you view operating expenses this year? - Management noted that investments in R&D and sales infrastructure are being made, but they remain focused on achieving positive cash flow without additional capital [44] Question: Will pediatric clarity impact the 2025 guidance? - Management confirmed that pediatric clarity will not impact the 2025 guidance but sees meaningful expansion potential in future years [46] Question: What is the competitive landscape like? - Management stated that they remain the clear category leader in point-of-care EEG and are not seeing significant competitive threats [66]

[PART I. FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) CeriBell, Inc. reported Q1 2025 total revenue of **$20.5 million**, a **42% increase** year-over-year, with a net loss of **$12.8 million** Condensed Balance Sheet Data (in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $153,360 | $194,370 | | Total current assets | $205,420 | $217,272 | | Total assets | $213,471 | $225,412 | | **Liabilities & Equity** | | | | Total current liabilities | $11,831 | $12,989 | | Total liabilities | $32,590 | $34,247 | | Total stockholders' equity | $180,881 | $191,165 | Condensed Statements of Operations Data (in thousands, except per share data) | | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Total revenue | $20,491 | $14,400 | | Gross profit | $18,007 | $12,342 | | Loss from operations | $(14,207) | $(8,453) | | Net loss | $(12,777) | $(8,521) | | Net loss per share (basic and diluted) | $(0.36) | $(1.56) | Condensed Statements of Cash Flows Data (in thousands) | | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(11,403) | $(9,550) | | Net cash used in investing activities | $(29,609) | $(132) | | Net cash provided by financing activities | $2 | $7,678 | | Net decrease in cash and cash equivalents | $(41,010) | $(2,004) | [Notes to Condensed Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) Notes detail liquidity, revenue disaggregation, new debt facilities, and increased stock-based compensation for Q1 2025 - The company has incurred operating losses since inception, with an accumulated deficit of **$179.7 million** as of March 31, 2025, but management believes existing cash and cash equivalents of **$182.7 million** are sufficient to fund operations for at least the next **12 months**[30](index=30&type=chunk)[31](index=31&type=chunk)[32](index=32&type=chunk) Disaggregation of Revenue (in thousands) | Revenue Source | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | EEG headbands, point in time | $15,608 | $11,035 | | EEG portal and Clarity subscriptions, over time | $4,883 | $3,365 | | **Total Revenue** | **$20,491** | **$14,400** | - In February 2024, the company executed a Venture Loan and Security Agreement for a **$50 million** term loan commitment, drawing an initial **$20 million**, and secured a **$10 million** senior revolving line of credit[75](index=75&type=chunk)[76](index=76&type=chunk)[81](index=81&type=chunk) - Total stock-based compensation expense was **$2.3 million** for Q1 2025, a significant increase from **$0.8 million** in Q1 2024, primarily driven by higher expenses in general & administrative and sales & marketing functions[100](index=100&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=32&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses **42% revenue growth** driven by Ceribell System adoption, **55% operating expense increase**, and **$12.8 million net loss** for Q1 2025 [Overview](index=32&type=section&id=Overview) CeriBell's core Ceribell System, an AI-powered EEG platform, has expanded to over **550 active accounts** and served over **200,000 patients** - The company's core product is the **Ceribell System**, an **AI-powered**, point-of-care EEG platform designed for rapid diagnosis and continuous monitoring of neurological conditions in acute care settings[110](index=110&type=chunk)[112](index=112&type=chunk) - As of March 31, 2025, the company has expanded its customer base to over **550 active accounts** and its system has been used to care for over **200,000 patients**[111](index=111&type=chunk) - The company's primary commercial focus is the **U.S. market**, which has approximately **6,000 acute care facilities**, and it also holds a **CE Mark** for Europe with plans for further international expansion[113](index=113&type=chunk) [Results of Operations](index=39&type=section&id=Results%20of%20Operations) Q1 2025 revenue grew **42% to $20.5 million**, gross profit **46% to $18.0 million**, but operating expenses surged **55% to $32.2 million**, widening loss to **$14.2 million** Results of Operations Comparison (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Total revenue** | **$20,491** | **$14,400** | **$6,091** | **42%** | | Product revenue | $15,608 | $11,035 | $4,573 | 41% | | Subscription revenue | $4,883 | $3,365 | $1,518 | 45% | | **Gross profit** | **$18,007** | **$12,342** | **$5,665** | **46%** | | **Total operating expenses** | **$32,214** | **$20,795** | **$11,419** | **55%** | | Sales and marketing | $18,033 | $10,576 | $7,457 | 71% | | **Loss from operations** | **$(14,207)** | **$(8,453)** | **$(5,754)** | **68%** | | **Net loss** | **$(12,777)** | **$(8,521)** | **$(4,256)** | **50%** | - Revenue growth was driven by the addition of new customers and increased utilization of headbands by existing customers[134](index=134&type=chunk)[135](index=135&type=chunk) - The increase in operating expenses was primarily due to higher personnel-related costs from increased headcount, with sales and marketing expenses rising by **$7.5 million** (**71%**)[139](index=139&type=chunk)[140](index=140&type=chunk)[141](index=141&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity of **$182.7 million** from October 2024 IPO proceeds and new debt facilities is deemed sufficient for the next **12 months** - The company completed its IPO on **October 15, 2024**, receiving net proceeds of **$187.8 million**[149](index=149&type=chunk) - As of March 31, 2025, principal sources of liquidity consisted of **$182.7 million** in cash, cash equivalents, and short-term marketable securities[151](index=151&type=chunk) - Management believes existing cash and expected revenue will be sufficient to fund planned operating expenses and capital expenditure requirements for at least the next **12 months**[154](index=154&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=45&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company has determined that quantitative and qualitative disclosures about market risk are not applicable - The company has determined that quantitative and qualitative disclosures about market risk are not applicable[160](index=160&type=chunk) [Controls and Procedures](index=45&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal controls - The CEO and CFO concluded that the company's disclosure controls and procedures were **effective** as of March 31, 2025[161](index=161&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[162](index=162&type=chunk) [PART II. OTHER INFORMATION](index=48&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=48&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any litigation expected to have a material adverse effect on its business - The company is not currently a party to any litigation that is expected to have a material adverse effect on its business[167](index=167&type=chunk) [Risk Factors](index=48&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant business, regulatory, and intellectual property risks, including a history of losses, dependence on a single product, intense competition, and complex healthcare compliance [Business and Industry Risk Factors](index=48&type=section&id=Business%20and%20Industry%20Risk%20Factors) Business risks include a history of net losses, dependence on the Ceribell System, intense competition, and reliance on Chinese manufacturers - The company has a history of net losses, incurring a loss of **$40.5 million** in fiscal year 2024, and expects to incur substantial losses in the foreseeable future[173](index=173&type=chunk) - The company faces competition from conventional EEG providers like **Natus** and **Nihon Kohden**, which have greater resources and brand recognition[180](index=180&type=chunk) - The company relies on manufacturers and suppliers in **China** for headband assembly and components, exposing it to foreign operational, political, and trade risks, including tariffs[184](index=184&type=chunk)[187](index=187&type=chunk)[188](index=188&type=chunk) [Risks Related to Regulatory Matters](index=64&type=section&id=Risks%20Related%20to%20Regulatory%20Matters) Regulatory risks involve uncertain third-party reimbursement, compliance with fraud and abuse laws, and stringent FDA regulations for medical devices - The ability to sell the Ceribell System profitably depends on adequate reimbursement from third-party payers, and the company's new Clarity algorithm received a New Technology Add-on Payment (**NTAP**) designation, which lasts for no more than **three years**[223](index=223&type=chunk)[224](index=224&type=chunk) - The company is subject to numerous federal and state healthcare fraud and abuse laws, including the **Anti-Kickback Statute** and **False Claims Act**, which constrain business and marketing practices[233](index=233&type=chunk)[236](index=236&type=chunk) - Products are regulated as medical devices by the **FDA** and require marketing authorization (e.g., **510(k) clearance**), and any modifications may require new submissions, with adherence to the **Quality System Regulation (QSR)** for manufacturing[248](index=248&type=chunk)[254](index=254&type=chunk)[273](index=273&type=chunk) [Risks Related to Our Intellectual Property](index=100&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) IP risks include protecting patents and trade secrets, potential infringement litigation, and dependence on an in-license from Stanford University - The company's success depends on its ability to obtain, maintain, and enforce its intellectual property rights, including **patents, trademarks, and trade secrets**[332](index=332&type=chunk) - The company may become party to **expensive and time-consuming** intellectual property litigation, and could be forced to cease commercializing products or pay substantial damages if found to be infringing on third-party rights[359](index=359&type=chunk)[361](index=361&type=chunk) - The company's "brain stethoscope" EEG sonification technology is protected by intellectual property rights in-licensed from **Stanford University**, and the business is subject to compliance with the terms of this license agreement[370](index=370&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=134&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity sales occurred; IPO proceeds of **$188.2 million** are used for sales, R&D, and general corporate purposes - On October 15, 2024, the company completed its IPO, receiving net proceeds of approximately **$188.2 million**[437](index=437&type=chunk) - The IPO proceeds are being used to fund sales and marketing, research and product development, and for general corporate purposes, with no material change from the intended use described in the prospectus[438](index=438&type=chunk)[439](index=439&type=chunk) [Defaults Upon Senior Securities](index=134&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon its senior securities - None[440](index=440&type=chunk) [Mine Safety Disclosures](index=134&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - Not applicable[441](index=441&type=chunk) [Other Information](index=134&type=section&id=Item%205.%20Other%20Information) This section details the adoption and termination of Rule 10b5-1 trading plans by company executives in March 2025 Rule 10b5-1 Trading Plans Activity | Name | Action | Date | Total Shares to be Sold | | :--- | :--- | :--- | :--- | | David Foehr | Terminate | Mar 4, 2025 | 17,223 | | David Foehr | Adopt | Mar 11, 2025 | 15,071 | | Scott Blumberg | Adopt | Mar 14, 2025 | 93,000 | | Rebecca Robertson | Adopt | Mar 14, 2025 | 40,426 | [Exhibits](index=136&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate governance documents and officer certifications - The report includes several exhibits, such as corporate governance documents, a separation agreement with Joshua Copp dated March 28, 2025, and required officer certifications[446](index=446&type=chunk)

[Ceribell First Quarter 2025 Financial Results](index=1&type=section&id=Ceribell%20First%20Quarter%202025%20Financial%20Results) [First Quarter 2025 & Recent Highlights](index=1&type=section&id=First%20Quarter%202025%20%26%20Recent%20Highlights) Ceribell achieved a strong start to 2025 with **42% revenue growth** to **$20.5 million**, expanding its active accounts and securing key regulatory approvals - CEO Jane Chao emphasized a strong start to the year, driven by expanded accounts and accelerated system adoption, with plans for continued growth to establish EEG as a new vital sign[3](index=3&type=chunk) - Ending the quarter with **558 total active accounts**[9](index=9&type=chunk) - Received U.S. FDA 510(k) clearance for the Clarity™ algorithm for patients aged 1 and older[9](index=9&type=chunk) - Became the first medical device company to receive FedRAMP High authorization from the U.S. federal government[9](index=9&type=chunk) Q1 2025 Key Financial Metrics | Metric | Value ($) | Change (YoY, %) | | :--- | :--- | :--- | | Total Revenue | $20.5 million | +42% | | Gross Margin | 88% | N/A | [First Quarter 2025 Financial Results](index=1&type=section&id=First%20Quarter%202025%20Financial%20Results) Ceribell's Q1 2025 revenue grew **42% to $20.5 million** with an **88% gross margin**, but increased operating expenses led to a **$12.8 million net loss** Q1 2025 vs Q1 2024 Revenue Breakdown | Revenue Type | Q1 2025 ($) | Q1 2024 ($) | Growth (%) | | :--- | :--- | :--- | :--- | | Product Revenue | $15.6 million | $11.0 million | +41% | | Subscription Revenue | $4.9 million | $3.4 million | +45% | | **Total Revenue** | **$20.5 million** | **$14.4 million** | **+42%** | Q1 2025 vs Q1 2024 Profitability | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Gross Profit ($) | $18.0 million | $12.3 million | | Gross Margin (%) | 88% | 86% | - Operating expenses increased by **55% to $32.2 million** from **$20.8 million** in Q1 2024, primarily due to investments in the commercial organization, increased headcount, and public company operating costs[6](index=6&type=chunk) Q1 2025 Net Loss and Cash Position | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Loss ($) | $12.8 million | $8.5 million | | Net Loss Per Share ($) | $0.36 | $1.56 | | **As of March 31, 2025** | | | | Cash, cash equivalents, and marketable securities ($) | $182.7 million | N/A | [2025 Financial Outlook](index=1&type=section&id=2025%20Financial%20Outlook) Ceribell raised its full-year 2025 revenue guidance to **$83 million to $87 million**, reflecting an anticipated **27% to 33% growth** - The company raised its full-year 2025 revenue guidance to a range of **$83 million to $87 million**[8](index=8&type=chunk) - The updated guidance represents an expected revenue growth of approximately **27% to 33%** over the prior year[8](index=8&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) Unaudited condensed financial statements for Ceribell, Inc. as of March 31, 2025, detail the quarter's operations and balance sheet position [Condensed Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Ceribell's Q1 2025 operations show **total revenue of $20.49 million** and a **net loss of $12.78 million** due to increased operating expenses Condensed Statement of Operations (in thousands) | Account | Three months ended March 31, 2025 (in thousands) | Three months ended March 31, 2024 (in thousands) | | :--- | :--- | :--- | | Total revenue | $20,491 | $14,400 | | Gross profit | $18,007 | $12,342 | | Total operating expenses | $32,214 | $20,795 | | Loss from operations | $(14,207) | $(8,453) | | Net loss | $(12,777) | $(8,521) | | Net loss per share | $(0.36) | $(1.56) | [Condensed Balance Sheets](index=5&type=section&id=Condensed%20Balance%20Sheets) As of March 31, 2025, Ceribell's balance sheet reflects **total assets of $213.47 million** and **stockholders' equity of $180.88 million** Condensed Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $153,360 | $194,370 | | Total current assets | $205,420 | $217,272 | | Total assets | $213,471 | $225,412 | | Total liabilities | $32,590 | $34,247 | | Total stockholders' equity | $180,881 | $191,165 | [Other Information](index=2&type=section&id=Other%20Information) Logistical and legal information, including investor call details, forward-looking statements, and a corporate overview, are provided [Webcast and Conference Call Details](index=2&type=section&id=Webcast%20and%20Conference%20Call%20Details) A conference call and webcast for Q1 2025 financial results were scheduled for May 8, 2025, at **1:30 p.m. PT** - A conference call to discuss Q1 2025 results was scheduled for May 8, 2025, at **1:30 p.m. PT**, with access via phone and a webcast available on the company's investor relations website[10](index=10&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) The release contains forward-looking statements subject to substantial risks and uncertainties, with actual results potentially differing materially - The release contains forward-looking statements concerning financial guidance, business strategy, and product expectations, which are subject to substantial risks and uncertainties[11](index=11&type=chunk) - Key risks include limited operating history, market adoption challenges, competitive pressures, manufacturing dependencies in China, and regulatory compliance[11](index=11&type=chunk) [About CeriBell, Inc.](index=2&type=section&id=About%20CeriBell%2C%20Inc.) Ceribell is a medical technology company providing an FDA-cleared, AI-powered point-of-care EEG system for rapid neurological diagnosis - Ceribell is a medical technology company that developed the Ceribell System, a point-of-care electroencephalography (EEG) platform for use in acute care settings[12](index=12&type=chunk) - The system combines portable hardware with AI-powered algorithms to enable rapid diagnosis and continuous monitoring of patients with suspected seizure activity[12](index=12&type=chunk)

Core Insights - CeriBell, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $20.5 million, a 42% increase from $14.4 million in Q1 2024, driven by new account adoption and expansion within existing accounts [4][11] - The company is optimistic about continued growth in 2025, focusing on physician education and product development, including the introduction of a pediatric Clarity algorithm [3][8] Financial Performance - Total revenue for Q1 2025 was $20.5 million, up 42% from $14.4 million in Q1 2024, with product revenue at $15.6 million (41% increase) and subscription revenue at $4.9 million (45% increase) [4][15] - Gross profit for Q1 2025 was $18.0 million, with a gross margin of 88%, compared to $12.3 million and 86% in Q1 2024 [5][11] - Operating expenses increased by 55% to $32.2 million in Q1 2025, primarily due to investments in the commercial organization and increased headcount [6][11] - The net loss for Q1 2025 was $12.8 million, or $0.36 per share, compared to a net loss of $8.5 million, or $1.56 per share, in Q1 2024 [7][11] Future Outlook - CeriBell raised its revenue guidance for the full year 2025 to a range of $83 million to $87 million, indicating a growth of approximately 27% to 33% over the previous year [8] - The company ended Q1 2025 with 558 total active accounts and received FDA clearance for the expansion of its Clarity algorithm, marking a significant milestone [11][11] Company Overview - CeriBell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions through its innovative EEG platform [13]

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time. Event ...

Core Insights - Ceribell has achieved FedRAMP High authorization, allowing its EEG technology to be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, enhancing rapid diagnosis for patients at risk of non-convulsive seizures [1][4][5] Group 1: Company Achievements - Ceribell is one of only 51 companies in the U.S. to receive FedRAMP High authorization, a significant cybersecurity credential that indicates compliance with the highest federal security standards [1][6] - The company's EEG system is already operational in VA hospitals following its Authority to Operate (ATO) in 2024, and the new authorization facilitates broader implementation across federal healthcare agencies [2][4] Group 2: Technology and Innovation - The Ceribell System is designed for rapid setup and continuous brain monitoring, combining portable hardware with AI-powered algorithms for quick diagnosis and ongoing patient monitoring [9] - The system is FDA-cleared for indicating suspected seizure activity and is currently utilized in intensive care units and emergency rooms across the U.S. [9] Group 3: Security and Compliance - FedRAMP High authorization reflects Ceribell's commitment to information security, ensuring that sensitive patient data is protected through rigorous security measures [5][7] - Less than 15% of FedRAMP Authorized systems meet the High security standard, highlighting the significance of Ceribell's achievement in this area [6]